Phospholipids
are lipids that constitute the basic structure of
cell membranes. In-depth research has shown that in addition to supporting
cell structures, phospholipids participate in multiple cellular processes,
including promoting cell signal transduction, guiding protein translocation,
activating enzymatic activity, and eliminating dysfunctional/redundant
organelles/cells. Diabetes is a chronic metabolic disease with a complicated
etiology and pathology. Studies have shown that the level of certain
phospholipids, for example, the ratio of phosphatidylcholine (PC)
to phosphatidylethanolamine (PE) in liver tissue, is negatively associated
with insulin sensitivity. In addition, PS is a phospholipid exhibiting
extensive cellular functions in diabetes. For this review, we analyzed
many PS studies focusing on diabetes and insulin sensitivity in recent
years and found that PS participates in controlling insulin secretion,
regulating insulin signaling transduction, and participating in the
progression of diabetic complications by mediating coagulation disorders
in the microvasculature or targeting mitochondria. Moreover, PS supplements
in food and PS-containing liposomes have been shown to protect against
type 1 and type 2 diabetes (T1D and T2D, respectively) in animal studies.
Therefore, by summarizing the regulatory roles played by PS in diabetes
and the potential of successfully using PS or PS-containing liposomes
for diabetic therapy, we hope to provide new ideas for further research
into the mechanisms of diabetes and for drug development for treating
diabetes and its complications.